The MUC1-C-integrated program provides support for the importance of this oncoprotein in cancer progression and emphasizes a critical need for developing agents against this widely overexpressed target in human malignancies.

The findings show that MUC1-C drives PD-L1 expression and represses effectors, such as interferon-gamma among others, of innate and adaptive immunity.  Targeting MUC1-C in human cancers thus represents a novel therapeutic strategy for reversing tumor-associated suppression of immune recognition and destruction.